Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.41 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20026739 | 0.98 | EPHX1 (0.45) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL25920320 | 0.98 | EPHX1 (0.45) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL21365174 | 0.88 | EPHX1 (0.42) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL21189718 | 0.84 | EPHX1 (0.39) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL19002169 | 0.83 | EPHX1 (0.40) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL20026584 | 0.83 | EPHX1 (0.40) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL20026472 | 0.81 | EPHX1 (0.42) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL25825777 | 0.81 | EPHX1 (0.42) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL23663781 | 0.79 | EPHX1 (0.43) | EPHX1KDM4CPAOXCA3CA5A | |
| SCHEMBL10330317 | 0.75 | EPHX1 (0.39) | EPHX1KDM4CPAOXKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4218795-A2 | PTH COMPOUNDS WITH LOW PEAK-TO-TROUGH RATIOS | Ascendis Pharma Bone Diseases A/S (DK) | 2023-08-02 | — | — | EP | disclosed |
| EP-3518960-B1 | DOSAGE REGIMEN FOR A CONTROLLED-RELEASE PTH COMPOUND | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-07-19 | — | — | EP | disclosed |
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | ASCENDIS PHARMA BONE DISEASES AS (DK) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218722-A1 | PTH Compounds with Low Peak-To-Trough Ratios | PTH1R, PTMS, FGF23 | EPHX1 1814/4885KDM4C 4210/4885PAOX 3905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.